newsfilter
← Latest News
Business Wire·

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

First clinical site for Phase 1/2 LuMIERE clinical study of novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP) now open for enrollment FAP-2286 is the first peptide-targeted radionuclide th